Alnylam Pharmaceuticals Inc (ALNY) Com Stk USD0.01

Sell:$243.62Buy:$243.78$3.38 (1.37%)

NASDAQ:2.64%
Market closed | Prices delayed by at least 15 minutes
Sell:$243.62
Buy:$243.78
Change:$3.38 (1.37%)
Deal now
Market closed | Prices delayed by at least 15 minutes
Sell:$243.62
Buy:$243.78
Change:$3.38 (1.37%)
Market closed | Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.

Key people

Yvonne L. Greenstreet
Chief Executive Officer, Director
Jeffrey V. Poulton
Chief Financial Officer, Executive Vice President
Kevin Fitzgerald
Executive Vice President, Chief Scientific Officer, Head - Early Research and Early Development
Pushkal P. Garg
Chief Medical Officer, Executive Vice President - Development and Medical Affairs
Michael W. Bonney
Chief Compliance Officer, Director
Tolga Tanguler
Chief Commercial Officer
Amy W. Schulman
Independent Chairman of the Board
Dennis A. Ausiello
Independent Director
Carolyn R. Bertozzi
Independent Director
Olivier Brandicourt
Independent Director
Margaret A. Hamburg
Independent Director
Click to see more

Key facts

  • EPIC
    -
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US02043Q1076
  • Market cap
    $31.94bn
  • Employees
    2,230
  • Shares in issue
    129.46m
  • Exchange
    NASDAQ
  • Index
    TR Equity United States Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.